The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds—those with high ...
The integration of artificial intelligence (AI) into drug discovery is revolutionizing pharmaceutical research by providing sophisticated tools for understanding and predicting complex biological ...
The current pharmaceutical landscape demands a change in mindset. Success requires balancing speed, cost and quality while ...
Hosted on MSN
Between hype and hope: Seattle biotech leaders size up AI’s real impact on drug development
Dozens of Seattle biotech companies are using artificial intelligence to design new medical treatments. But at a conference of industry leaders and investors this week, scientists delivered a nuanced ...
New Delhi: In a move to spur drug innovation and restore fairness in the regulatory ecosystem, India’s top drug authority plans to overhaul a rule that puts early applicants for new medicines at a ...
Raising Up to $5 Million to Support Rapid Expansion of Breakthrough, Clinically Proven Unbuzzd Beverage Hosting Live Webinar ...
Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today ...
During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius, will discuss the current investment ...
A researcher has proposed a more targeted approach to AI drug discovery, which includes a rigorous evaluation protocol.
Nguyen Phuong Ngan, 23, has just graduated as the valedictorian of Hanoi University of Pharmacy in 2025, earning a GPA of 3.81/4. Five years ago, she also topped the university’s entrance exam. For ...
Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback